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Objective:  The  study  was  designed  to  assess  the  prevalence,  management  and survival  of  patients  with
simultaneous  squamous  cell  carcinomas  of  the oral  cavity  and  hypopharynx  (OC/HP).
Material  and  methods:  A multicenter,  retrospective  study  (2 university  hospitals)  was  conducted  between
2003 and  2007  on a series  of  96  patients  with  simultaneous  squamous  cell  cancers  of  the OC/HP.
Results:  A  total  of  88  men  and  8 women  were  included  in the  study:  81  patients  presented  double  sites,
14  presented  triple  sites  and  one  presented  quadruple  sites.  The  tumour  sites  most  frequently  observed
were:  hypopharynx  in  61% of  cases  (involving  the pyriform  sinus  in 42%  of  cases)  and  the  orophar-
ynx in 59%  of cases  (involving  the  palatine  tonsil  in  30%  of  cases).  Upper  aerodigestive  tract  endoscopy
under  general  anaesthesia  revealed  a  simultaneous  lesion  not  suspected  on  clinical  examination  in 45%
of  patients:  the  site  discovered  on  endoscopy  was  hypopharyngeal  in 2 out of  3 cases;  the tumour  was
classiﬁed  T1  or T2  in  95.5%  of cases.  Patients  treated  simultaneously  for all  sites  had a better  prognosis
than  patients  in whom  each  tumour  was  treated  separately.  The  5-year  speciﬁc  survival  was  34%  and  the
5-year  overall  survival  was  28%.
Conclusion:  The  prevalence  of  simultaneous  squamous  cell  carcinomas  of the  oral  cavity  and  hypopharynx
ranges  between  1 to 7.4%  in  the  literature  and  was  4.6%  in the  present  series.  A  common  treatment  strategy
for  each  of the  patient’s  tumours  appears  to be superior  to the  current  theoretical  approach  that  consists
of  considering  each  tumour  separately.. Introduction
Since the ﬁrst description by Billroth in the 19th century, a large
umber of studies have described the phenomenon of multiple
ancers. However, few studies on simultaneous cancers of the oral
avity and hypopharynx have been published in the literature, but
he management of these tumours raises speciﬁc problems. This
rticle is designed to contribute to the study of these cancers based
n clinical observation of a series of 96 patients managed in head
nd neck surgery departments at Amiens and Lille university hos-
itals between January 2003 and December 2007.
. Material and methodsThe medical charts of 2096 patients with primary cancer of
he oral cavity and hypopharynx (OC/HP) were retrospectively
DOI of original article: http://dx.doi.org/10.1016/j.aforl.2014.02.003.
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reviewed and 96 patients with simultaneous squamous cell car-
cinoma of the OC/HP were selected.
Inclusion criteria of these patients were:
• at least two  simultaneous squamous cell carcinomas of the
OC/HP;
• no previous history of cancer;
• no other simultaneous cancers other than in the OC/HP.
Paranasal sinus and nasopharyngeal tumours, due to their
different epidemiology, and oesophageal and lung cancers were
excluded. Data collection comprised epidemiological and histologi-
cal parameters, anatomical distribution and tumour stage, and data
concerning the treatment strategy and follow-up. Data collection
was performed in two different centers, but by the same person.
Survival was  analysed according to the Kaplan–Meier method and
statistical analysis was  based on the log rank method and Chi2 test.
Multivariate analyses were performed according to the Cox model.
A P value less than 0.05 was  considered signiﬁcant.
Initial staging comprised the same examinations in both
centers:
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Table 1
Distribution of tumour sites in patients with multiple cancers.
Number of tumours for each site (208)
Oral cavity n = 39 (19%)
Floor of the mouth 23 (11%)
Mobile tongue 9
Oral commissure 7
Oropharynx n = 67 (32%)
Palatine tonsil 30 (14%)
Vallecula 11
Soft palate 13
Base of tongue 5
Posterior wall 5
Glosso-epiglottic fold 1
Junctional zone 2
Larynx n = 29 (14%)
Epiglottis 9
Vocal cord 10
Ventricular band 2
Aryepiglottic fold 5
Arytenoid 2
Hemilarynx 1
Hypopharynx n = 73 (35%)
Pyriform sinus 49 (24%)
Pharyngeal wall 13
Proximal oesophagus 284 P. Boute et al. / European Annals of Otorhinolary
endoscopy under general anaesthesia, including oropharyngo-
laryngoscopy;
contrast-enhanced CT scan of the neck and mediastinum;
upper GI ﬁbroscopy and bronchoscopy.
The primary objective of the study was to determine the inci-
ence of simultaneous OC/HP cancers. The secondary objectives
ere to evaluate the yield of endoscopic screening, identify patient
roups at high risk of developing these simultaneous cancers, and
nally analyse the management and survival of patients with mul-
iple cancers.
The criteria used to deﬁne multiple cancers were established in
932 by Warren and Gates [1] and were modiﬁed by Moertel [2].
These criteria are:
each distinct tumour must be conﬁrmed histologically;
the possibility that one of the two tumours is a metastasis from
the other tumour must be excluded;
each tumour must be separated from the healthy mucosa by at
least 1.5 cm (with no submucosal communication).
Finally, multiple cancers were classiﬁed into three groups
ccording to their chronological order:
simultaneous cancers are those diagnosed at the same time as
the ﬁrst tumour;
synchronous cancers are those diagnosed during the six months
following the diagnosis of the ﬁrst tumour;
metachronous cancers are those diagnosed more than six months
after the diagnosis of the ﬁrst tumour.
. Results
The frequency of simultaneous cancers involving the OC/HP was
herefore 4.6% (96/2096). This series comprised 88 men  (92%) and
 women (8%) with a mean age of 55 years (range: 40–75 years).
he sex ratio was 1 female for 11 males. A history of smoking and
rinking was reported by 89 patients (93%). The distribution by
tage according to the UICC TNM classiﬁcation was based on the
tage of the most advanced tumour. This series comprised 12% of
tage I, 15% of stage II, 21% of stage III, and 52% of stage IV tumours.
.1. Anatomical distribution of simultaneous cancers
Eighty-one of these 96 patients had double tumour sites, 14 had
riple tumour sites and one patient had quadruple tumour sites. The
elative frequency of each anatomical site in this series of simulta-
eous cancers was determined on the basis of all tumours observed
Table 1).
This analysis demonstrated a very marked variability of the fre-
uency of multiple cancers according to the tumour site (14% for
he larynx and 32% and 35% for the oropharynx and hypopharynx,
espectively). The larynx appeared to be underrepresented as a site
f simultaneous cancers. In contrast, the oropharynx and especially
he hypopharynx presented a higher risk of multifocal tumours. The
yriform sinus accounted for almost two-thirds of all hypopharyn-
eal tumours, while the tonsil accounted for almost one half of all
ropharyngeal tumours.
.2. Endoscopic ﬁndingsEndoscopy demonstrated a simultaneous tumour site not sus-
ected on the initial clinical examination in 45% of patients (n = 43).
he tumour sites discovered on endoscopy predominantly con-
erned the hypopharynx (64%), especially the pyriform sinus (42%).“Three-fold” region 7
Retrocricoid 2
The tumours discovered at endoscopy logically corresponded to
less advanced tumours (95% of Tis, T1, and T2 tumours).
3.3. Treatment
Various treatment strategies were applied to each of these
208 tumours considered separately, as summarized in Fig. 1.
Patients managed by symptomatic treatment (n = 6) or palliative
chemotherapy (n = 3) were classiﬁed separately (9 patients, 19
sites).
Patients were classiﬁed into three groups according to the treat-
ment strategy:
• common treatment group: all of the patient’s tumours were
treated according to the same treatment strategy;
• dissociated T treatment group: each of the patient’s tumours were
treated in a different way;
• dissociated T/N treatment group: different treatment modalities
were proposed for the patient’s tumours and lymph nodes.
3.4. Follow-up
Three patients were lost to follow-up. The mean follow-up was
32 months (range: 1–89 months). Progressive disease was observed
in 27 patients (29%). No synchronous cancers were observed in this
series. Nine patients developed a metachronous cancer (9.7%)., 16
patients (17%) developed local recurrence, 21 patients (23%) devel-
oped metastases during follow-up and 5 patients (5.4%) developed
lymph node recurrence.
3.5. Survival
Sixty-seven (72%) of the 93 patients of the series have died.
Mean survival was  24 months. The ﬁve-year speciﬁc survival, i.e.
the survival related to head and neck cancer was 34%, while the
ﬁve-year overall survival was 28%. Survival curves were plotted
according to the Kaplan–Meier method (Fig. 2). Univariate anal-
ysis of several parameters likely to inﬂuence survival was then
performed using the log rank method. As expected TNM tumour
stage and lymph node status had a statistically signiﬁcant impact on
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Fig. 1. Distribution of the various tr
urvival (P = 0.0001 for both parameters): advanced tumour stage
nd lymph node status were pejorative parameters for overall sur-
ival. Poorly differentiated histology also had a negative impact ver-
us well or moderately well differentiated histology (P = 0.01). Body
ass index (BMI) was also identiﬁed as a factor affecting survival
P = 0.04), allowing patients to be classiﬁed into three groups: BMI
ess than 18, BMI  between 18 and 25 and BMI  greater than 25. Sur-
ival improved with increasing BMI. Gender was a discriminant fac-
or for survival (P = 0.005) with signiﬁcantly better survival for men.
Finally, comparison of the various types of treatment revealed
 signiﬁcant difference (P = 0.04): the group of patients receiving
ommon treatment for all tumours obtained a better survival than
he T/N and T dissociated treatment groups.
The number of tumours (2/3.4), the severity of smoking, and age
ere not identiﬁed as signiﬁcant risk factors on univariate anal-
sis. However, analysis according to three age groups (younger
han 50 years, 50 to 60 years, older than 60 years) demonstrated
 tendency to better survival for older patients.
Multivariate analysis was then performed on the following
arameters likely to affect survival: histological differentiation, age,
ender, TNM stage, BMI, type of treatment. TNM stage (P = 0.003)
nd BMI  (P = 0.001) were the only parameters with a signiﬁcant and
imilar impact on overall survival.
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Fig. 2. Overall survival curve (Kaplan–Meier).symptomatic  treatme nt
nt modalities for each tumour site.
4. Discussion
4.1. Epidemiology
The incidence of multiple cancers and especially simultaneous
cancers of the OC/HP reported in the literature varies consider-
ably according to the population studied, the inclusion criteria (for
example, whether or not carcinoma in situ is included), the inclu-
sion or exclusion of lung and oesophageal tumours and the study
methodology (prospective or retrospective study, with or without
systematic endoscopy) [3].
The incidence of simultaneous tumours located in the OC/HP
in a patient with squamous cell carcinoma ranges from 1 to 7.4%
(Table 2). Prospective studies using systematic endoscopy pub-
lished by Gluckman [4] and McGuirt [3] have reported higher rates
of multiple tumours. It is difﬁcult to compare the results of these
various studies conducted according to very different methodolo-
gies, but the incidence of 4.5% reported in our study appears to be
consistent with the mean incidence rates reported in the literature.
The incidence of three or more tumours was 0.71% in our study,
while rates varying between 0.25 and 1.8% are reported in the liter-
ature, indicating that three or more simultaneous tumours remain
exceptional [5].
Metastases were present at diagnosis in 3% of patients in our
study, similar to the rate of 3.9% reported by Panosetti et al., and
does not appear to be higher than the rate observed for single head
and neck cancers [6].
4.2. Anatomical distribution of simultaneous cancers
Few studies in the literature have been speciﬁcally devoted to
the analysis of simultaneous OC/HP cancers. The study by Pasche
[7] demonstrated a predisposition for certain sites: 50% of patients
with cancer of the soft palate presented multiple tumours. How-
ever, in addition to patients with simultaneous carcinoma of the
Table 2
Incidence of simultaneous cancers reported in the literature.
Author Incidence of
simultaneous tumours
in all sites (including
lung, oesophagus) (%)
Incidence of
simultaneous tumours
of the OC/HP (%)
Gluckman [4] 9.2 7.4
Shapsay et al. [5] 14 6
McGuirt [3] 16 6
Panosetti et al. [6] 4.1 2.4
Jones et al. [7] 1 –
Ricard et al. [8] – 1
Haerle et al. [9] 4.8 2.8
Rennemo et al. [10] 1.3 –
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C/HP, this study also included patients with simultaneous lung
nd oesophageal cancers.
A different distribution was observed in our study: tumours of
he soft palate represented only 6% of all patients of this series,
hile tumours of the hypopharynx were present in 61% of patients.
umours of the oropharynx were observed in 59% of patients of
his series. These differences can possibly be explained by the fact
hat lung and oesophageal tumours were included in the study by
asche [7] and by the high rate of simultaneous soft palate, lung
nd oesophageal tumours.
.3. Role of endoscopic screening
A general consensus has now been reached concerning the value
f endoscopy, as it allows biopsies designed to conﬁrm the histolog-
cal diagnosis and also allows local tumour staging in order to assess
esectability. An additional beneﬁt of screening endoscopy is that it
ay  reveal early lesions, as in many cases, only the largest lesion is
esponsible for symptoms. In 45% of patients in the present series,
creening endoscopy revealed a second or even a third tumour site,
llustrating the limitations of armchair ENT examination.
Patients with cancers of the OC/HP classically consult a specialist
nly at an advanced stage of disease: 73% of patients in this series
resented stage III or IV disease. In contrast, the majority of tumours
evealed by endoscopy were detected at an early stage (95.5% were
tage T1, T2 tumours).
However, the value of systematic endoscopic work-up remains
ontroversial in the literature.
Several authors [3,8] have shown that the double tumour rate
as two-fold higher with the use of systematic endoscopy and have
ecommended that this examination be performed systematically.
However, other authors believe that endoscopic screening has
 low yield and do not recommend systematic use of this examina-
ion [9,10]. For example, Cianfriglia et al. [9] reported a 1% rate of
imultaneous tumours discovered during endoscopy.
In our experience, endoscopy, at least oropharyngolaryn-
oscopy, appears to be essential, as it demonstrated almost one
alf of all simultaneous tumours of this series.
However, only a few studies tend to suggest that early detection
f simultaneous tumours actually improves survival [3,9], but early
etection of simultaneous tumours may  inﬂuence treatment of the
rst tumour and especially avoid mutilating treatment by leaving a
econd tumour in place. The absence of synchronous cancers in our
eries appears to validate the reliability of the initial endoscopic
creening.
.4. Treatment
Due to the diversity of the clinical situations encountered, a
tandard treatment strategy cannot be proposed and no deﬁni-
ive conclusions can be drawn. In the literature, although based on
nsufﬁcient data, it is generally recommended to treat each lesion
s if it were a solitary lesion. However, most patients (75%) in
he present series were treated according to a common treatment
odality for each tumour site. This common treatment predom-
nantly (65%) consisted of chemoradiotherapy. In this series, as
or single cancers, exclusive surgery was reserved for small T1
umours, mainly involving the oral cavity. In this exceptional situa-
ion, exclusive surgery in these selected cases avoided the need for
djuvant radiotherapy. The group of patients treated exclusively by
adiotherapy ± chemotherapy corresponded to very diverse situa-
ions, preventing any signiﬁcant conclusions.
The dissociated T treatment strategy proved to be of limited
alue in this series (n = 17) and was mainly used (in one half of
ases) for patients with triple tumours. This strategy also appearsy, Head and Neck diseases 131 (2014) 283–287
to be associated to a poorer prognosis than the common treatment
strategy.
A common treatment strategy for each of the patient’s tumours
appears to be the most appropriate approach in our experience,
which could possibly lead to a revision of the current approach
based on treating each tumour as if it were an isolated tumour.
Finally, dissociated tumour/lymph node treatment was reserved
to patients with advanced lymph node disease (N2, N3). It is there-
fore logical that this group presented poorer survival rates.
In the series published by McCollough et al. [11], 80% of lesions
were treated by chemoradiotherapy, which currently appears to
have a leading role in the management of these simultaneous can-
cers. It has the advantage of administering only a single sequence
of treatment and therefore avoids delaying the management of a
second or third tumour.
However, the use of radiotherapy for two  separate tumours con-
siderably increases the treatment volume, adverse effects and the
risk of radiation-induced complications [11].
Several questions remain unresolved: what is the efﬁcacy of
radiotherapy compared to a combination of surgery and radiother-
apy? What is the effect of irradiation on this high-risk mucosa?
4.5. Survival
Calculation of overall survival rates for patients with multiple
cancers is of limited value in view of the diverse characteristics of
these patient populations. However, overall survival rates can be
used to compare this group of patients with simultaneous OC/HP
cancers with the population of head and neck cancers as a whole.
The 5-year overall survival rate is therefore about 35% for head and
neck cancers in general [12]. The 5-year speciﬁc survival (34%) in
our population was  similar to the overall survival rate for head and
neck cancers, but the 5-year overall survival was slightly differ-
ent, with a value of 28%. Simultaneous cancers therefore appear to
have a slightly poorer prognosis, but it nevertheless appears to be
similar to that of squamous cell carcinomas of the head and neck,
raising the question of whether multiple tumours are really asso-
ciated with a poorer prognosis or whether the prognosis is simply
related to the prognosis of the most advanced tumour.
McCollough et al. [11] reported a 5-year overall survival rate of
14% in a population identical to that of the present series, com-
prising 75% of stage III and IV patients compared to 73% in our
study. According to McCollough et al., simultaneous lesions appear
to be associated with a considerably poorer prognosis. Pasche [7]
reported a 3-year overall survival rate of 22%.
Other published series have analysed simultaneous cancers
involving all sites (including oesophagus and lung) and therefore
reported poorer survival rates, but these results cannot be com-
pared to those of our series due to the inclusion of simultaneous
tumours with completely different prognoses.
Analysis of the various prognostic factors showed that nodal
status, TNM stage and histological differentiation remain the major
prognostic factors in this particular population, as in the population
with single cancers.
BMI  is a useful prognostic factor, as it can be easily determined at
the time of diagnosis. Univariate and multivariate analysis showed
that overweight patients (BMI greater than 25), despite the possi-
ble comorbidities related to this state, presented a better overall
survival.
5. ConclusionThis study highlights the problem of simultaneous tumours of
the OC/HP, which are observed in one out of every 22 patients.
The essential ﬁndings of this study are as follows:
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in total, 4.6% of patients with head and neck cancer have a simul-
taneous tumour of the OC/HP;
cancers of the pyriform sinus and palatine tonsil are associated
with a high incidence of multifocal tumours (42% and 30% of
patients presenting at least one of these tumour sites, respec-
tively);
detection of a second tumour site in the OC/HP is based on sys-
tematic screening endoscopy, which demonstrated one or several
simultaneous lesions in 45% of patients;
treatment evaluation is essential in this group of patients, which
raises speciﬁc problems. This evaluation is justiﬁed by the rela-
tively comparable survival rates to those of single cancers (5-year
speciﬁc survival: 34%, 5-year overall survival: 28%);
in the absence of treatment guidelines, multidisciplinary consul-
tation remains essential in these patients.
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